003220 — Daewon Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedSmall CapNeutral

Market Cap
KR₩281bn
Enterprise Value
KR₩431bn
Revenue
KR₩598bn

Annual income statement for Daewon Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	308,501	354,176	478,885	526,952	598,162
Cost of Revenue
Gross Profit	165,937	176,468	237,942	257,247	287,330
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	285,118	335,862	438,032	499,316	572,443
Operating Profit	23,383	18,314	40,853	27,636	25,719
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	23,642	17,136	38,722	25,830	16,159
Provision for Income Taxes
Net Income After Taxes	17,198	6,611	30,657	23,463	10,104
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	17,640	6,989	31,944	23,917	14,210
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	17,640	6,989	31,944	23,917	14,210
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	851	363	1,589	1,332	791
Dividends per Share